mental retardation: ['Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual is mentally retarded. IQ scores between 70 and 79 are in the borderline mentally retarded range. Scores below 67 are in the retarded range. (Joynt, Clinical Neurology, 1992, Ch55, p28)']
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
230 |
4. Check minimum number of eventsNone |
230 |
5. Include endpointsNone |
230 |
6. Filter based on genotype QC (FinnGen only) |
230 |
Control definitions (FinnGen only)
- Control exclude
- F5_MENTRET
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- F70-F79
- Name in latin
- Retardatio mentalis moderata
Similar endpoints
↥List of similar endpoints to
Moderate mental retardation
based on the number of shared cases.
Similar with more cases:
- Mental retardation
- Mental retardation, excluding more controls
- Mental retardation, wide definition
- Psychiatric diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 8871 | 3898 | 4958 |
| Only index persons | 7776 | 3383 | 4393 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.13 | 0.11 | 0.14 |
| Only index persons | 0.15 | 0.12 | 0.17 |
| Median age at first event (years) | |||
| Whole population | 20.27 | 22.12 | 18.75 |
| Only index persons | 19.66 | 21.47 | 18.26 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 230 | 109 | 121 |
| Unadjusted period prevalence (%) | 0.05 | 0.04 | 0.05 |
| Median age at first event (years) | 21.35 | 22.82 | 20.02 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 214
- Matched controls
- 2138
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
F71.0
ICD-10 Finland
Moderate mental retardation, with the statement of no, or minimal, impairment of behaviour
1815.1
112.1
99
*
F70.0
ICD-10 Finland
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
921.1
70.2
65
*
F71.1
ICD-10 Finland
Moderate mental retardation, significant impairment of behaviour requiring attention or treatment
+∞
66.1
60
*
113
Kela drug reimbursment
Anxiety disorders associated with mental retardation
+∞
55.7
51
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
26.6
54.9
78
45
N03AG01
ATC
valproic acid; systemic, rectal
20.9
53.9
84
64
F70.1
ICD-10 Finland
Mild mental retardation, Significant impairment of behaviour requiring attention or treatment
+∞
44.3
41
*
N05AX08
ATC
risperidone; systemic
15.1
43.0
76
75
F79.0
ICD-10 Finland
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
499.1
42.7
41
*
F71.9
ICD-10 Finland
Moderate mental retardation, without mention of impairment of behaviour
+∞
42.1
39
*
G40.9
ICD-10 Finland
Epilepsy, unspecified
28.7
41.0
56
26
N05BA01
ATC
diazepam; systemic, rectal
10.1
36.7
81
121
P85
ICPC
Mental retardation
215.1
35.9
36
*
N05AA02
ATC
levomepromazine; systemic
22.5
32.9
48
27
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
9.8
32.6
72
105
N03AF01
ATC
carbamazepine; oral, rectal
20.3
31.7
48
30
183
Kela drug reimbursment
Lamotrigin and topiramate
52.0
29.7
35
8
F70.9
ICD-10 Finland
Mild mental retardation, Without mention of impairment of behaviour
335.0
29.5
29
*
N05BA09
ATC
clobazam; oral
55.4
28.4
33
7
F79.9
ICD-10 Finland
Unspecified mental retardation, without mention of impairment of behaviour
+∞
26.6
25
*
N03AX11
ATC
topiramate; oral
17.8
23.0
36
24
N03AX14
ATC
levetiracetam; systemic
17.8
23.0
36
24
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
18.8
22.8
35
22
N05CD08
ATC
midazolam; nasal, systemic
17.3
21.6
34
23
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
26.6
20.6
28
12
N05AC02
ATC
thioridazine; oral
32.6
20.2
26
9
31299
ICD-8 Finland
Moderate mental retardation, Other and unspecified
+∞
20.1
19
*
F83
ICD-10 Finland
Mixed specific developmental disorders
20.7
19.7
29
16
N03AX09
ATC
lamotrigine; oral
8.4
18.9
43
62
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
6.8
18.4
49
89
R62.0
ICD-10 Finland
Delayed milestone
20.4
18.3
27
15
F72.0
ICD-10 Finland
Severe mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
18.0
17
*
N05AH03
ATC
olanzapine; systemic
6.9
16.6
43
75
N04AA02
ATC
biperiden; systemic
27.0
16.4
22
9
R56.8
ICD-10 Finland
Other and unspecified convulsions
6.8
16.0
42
74
A06AD11
ATC
lactulose; oral
5.4
15.7
51
118
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
19.6
15.5
23
13
F71
ICD-10 Finland
Moderate mental retardation
+∞
14.8
14
*
N03AG04
ATC
vigabatrin; oral
160.5
14.7
15
*
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
29.6
14.5
19
7
N03AF02
ATC
oxcarbazepine; oral
11.3
14.5
27
27
N05AD01
ATC
haloperidol; systemic
12.1
13.9
25
23
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
5.4
13.9
44
98
3180A
ICD-9 Finland
Other specified mental retardation, Moderate mental retardation[KESKIVAIKEA ÄLYLL KEHITYSVAMMAISUUS,EI KÄYTÄYT.HÄIR]
+∞
13.7
13
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
6.0
13.6
39
77
G40.89
ICD-10 Finland
Other epilepsy
43.0
13.3
16
*
G40.4
ICD-10 Finland
Other generalized epilepsy and epileptic syndromes
53.4
13.0
15
*
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
34.4
12.8
16
5
181
Kela drug reimbursment
Retigabine and vigabatrin
137.7
12.6
13
*
N05AF03
ATC
chlorprothixene; systemic
17.2
12.4
19
12
G40.10
ICD-10 Finland
Simple partial seizures
24.5
11.8
16
7
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
5.0
11.7
39
92
78159
ICD-8 Finland
Other symptoms referable to nervous system and special senses, Laesio loquendi alia sive NUD
+∞
11.6
11
*
G40.39
ICD-10 Finland
Other or unspecified generalized epileptic syndromes with atonic, clonic, myoclonic or tonic-clonic seizures
37.2
11.4
14
*
G03DC03
ATC
lynestrenol; oral
11.0
11.3
21
21
Z01.1
ICD-10 Finland
Examination of ears and hearing
3.8
11.0
50
159
N03AE01
ATC
clonazepam; systemic
6.9
10.9
27
44
H50.30
ICD-10 Finland
Intermittent esotropy
29.8
10.9
14
5
N05AH02
ATC
clozapine; systemic
12.1
10.8
19
17
N03AF03
ATC
rufinamide; oral
+∞
10.5
10
*
3170A
ICD-9 Finland
Mild mental retardation[LIEVÄ ÄLYLL.KEHITYSVAMMAISUUS,EI KÄYTÄYTYM.HÄIRIÖTÄ]
+∞
10.5
10
*
3199A
ICD-9 Finland
Unspecified mental retardation[MUU ÄLYLLINEN KEHITYSVAMMAISUUS,EI KÄYTTÄYTYMIHÄIRI]
+∞
10.5
10
*
F29
ICD-10 Finland
Unspecified nonorganic psychosis
6.2
10.4
28
51
M01AH05
ATC
etoricoxib; oral
0.3
10.3
26
696
N05AH04
ATC
quetiapine; oral
3.2
10.0
61
239
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.1
9.9
64
261
R1260
NOMESCO Finland
Evaluation of communicative skills
10.8
9.7
18
18
G40.00
ICD-10 Finland
Benign childhood epilepsy with centrotemporal EEG spikes
104.5
9.5
10
*
F79.1
ICD-10 Finland
Unspecified mental retardation, significant impairment of behaviour requiring attention or treatment
+∞
9.4
9
*
A28
ICPC
Limited function/disability NOS
3.9
9.3
39
115
SDA02
NOMESCO Finland
Parodonthologic therapy
2.6
9.3
94
502
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.9
9.1
39
117
N05AA01
ATC
chlorpromazine; systemic, rectal
19.7
9.0
13
7
G40.19
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
25.3
9.0
12
5
F20.9
ICD-10 Finland
Schizophrenia, unspecified
10.7
8.7
16
16
H50.31
ICD-10 Finland
Intermittent exotropia
13.5
8.5
14
11
Z31.5
ICD-10 Finland
Genetic counselling
5.1
8.5
26
56
F72.1
ICD-10 Finland
Severe mental retardation, significant impairment of behaviour requiring attention or treatment
+∞
8.4
8
*
199
Kela drug reimbursment
Rufinamide
+∞
8.4
8
*
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
8.1
8.4
18
24
RL140
NOMESCO Finland
NA
15.3
8.3
13
9
H50.1
ICD-10 Finland
Divergent concomitant strabismus
18.0
8.2
12
7
H52.2
ICD-10 Finland
Astigmatism
7.8
8.2
18
25
N88
ICPC
Epilepsy
34.8
8.1
10
*
N03AB02
ATC
phenytoin; systemic
34.8
8.1
10
*
ADB00
NOMESCO Finland
Implantation of vagus nerve stimulating device
34.8
8.1
10
*
N03AX15
ATC
zonisamide; oral
23.1
8.1
11
5
N03AX22
ATC
perampanel; oral
23.1
8.1
11
5
N05BA06
ATC
lorazepam; systemic, sublingual
6.2
8.1
21
37
R1210
NOMESCO Finland
Medical assessment of need and possibilities to rehabilitation
11.4
7.9
14
13
M03BX02
ATC
tizanidine; oral
0.4
7.9
36
755
WYA20
NOMESCO Finland
Home visit
15.8
7.8
12
8
N03AX18
ATC
lacosamide; systemic
19.2
7.7
11
6
N05AX12
ATC
aripiprazole; systemic
5.0
7.5
23
50
Q85.1
ICD-10 Finland
Tuberous sclerosis
82.8
7.5
8
*
G80.1
ICD-10 Finland
Spastic diplegic cerebral palsy
82.8
7.5
8
*
Z36.3
ICD-10 Finland
Antenatal screening for malformations using ultrasound and other physical methods
0.0
7.5
*
178
R1100
NOMESCO Finland
General evaluation of the need for rehabilitation
7.8
7.3
16
22
F79
ICD-10 Finland
Unspecified mental retardation
+∞
7.3
7
*
3180B
ICD-9 Finland
Other specified mental retardation, Moderate mental retardation[KESKIVAIKEA ÄLYLL KEHITYSVAMMAISUUS JA KÄYTÄYT.HÄIR]
+∞
7.3
7
*
3170B
ICD-9 Finland
Mild mental retardation[LIEVÄ ÄLYLL.KEHITYSVAMMAISUUS,JOSSA KÄYTÄYTYM.HÄIRI]
+∞
7.3
7
*
31099
ICD-8 Finland
Borderline mental retardation, Other and unspecified
+∞
7.3
7
*
G80.9
ICD-10 Finland
Cerebral palsy, unspecified
+∞
7.3
7
*
31209
ICD-8 Finland
Moderate mental retardation, Following infections and intoxications, Unspecified
+∞
7.3
7
*
N05AF05
ATC
zuclopenthixol; systemic
16.5
7.3
11
7
JDB10
NOMESCO Finland
Percutaneous gastrostomy
31.2
7.2
9
*
R1410
NOMESCO Finland
Drawing up a rehabilitation plan
20.9
7.2
10
5
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
4.6
7.2
24
57
F20.00
ICD-10 Finland
Paranoid schizophrenia continuous
9.3
7.2
14
16
R33
ICD-10 Finland
Retention of urine
5.9
7.1
19
35
Z01.8
ICD-10 Finland
Other specified special examinations
2.6
7.0
57
263
O80.0
ICD-10 Finland
Spontaneous vertex delivery
0.0
7.0
*
196
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.5
7.0
59
279
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.9
6.8
27
76
M01AB05
ATC
diclofenac; systemic, rectal
0.4
6.8
45
828
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
2.3
6.8
83
470
34599
ICD-8 Finland
Epilepsy, Other and unspecified
23.4
6.7
9
*
7803A
ICD-9 Finland
General symptoms, Convulsions
23.4
6.7
9
*
Z2446
NOMESCO Finland
Social worker
3.2
6.7
35
123
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
10.5
6.6
12
12
OAB43
SPAT
NA
0.1
6.6
*
210
EBA15
NOMESCO Finland
Extraction of large number of teeth
5.5
6.5
18
35
K05.10
ICD-10 Finland
Gingivitis (chronic) NOS
2.8
6.5
43
175
G40.1
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
71.9
6.5
7
*
G40.30
ICD-10 Finland
Benign myoclonic eplilepsy in infancy
71.9
6.5
7
*
3454A
ICD-9 Finland
Epilepsy, Partial epilepsy, with impairment of consciousness[EPILEPSIA GENERALISATA SECUNDARIA]
71.9
6.5
7
*
3459X
ICD-9 Finland
Epilepsy, unspecified
71.9
6.5
7
*
7834D
ICD-9 Finland
Symptoms concerning nutrition, metabolism and development, Lack of expected normal physiological development[LAPSEN NORMAALIN KEHITTYMISEN HIDASTUMINEN]
71.9
6.5
7
*
M41.4
ICD-10 Finland
Neuromuscular scoliosis
71.9
6.5
7
*
N05AB03
ATC
perphenazine; systemic, rectal
6.9
6.5
15
23
N05AD03
ATC
melperone; systemic
14.9
6.5
10
7
TLC00
NOMESCO Finland
Insertion of intrauterine device
4.5
6.3
21
50
L28
ICPC
Limited function/disability (L)
3.0
6.3
37
141
31199
ICD-8 Finland
Mild mental retardation, Other and unspecified
+∞
6.3
6
*
F84.0
ICD-10 Finland
Childhood autism
+∞
6.3
6
*
F84.9
ICD-10 Finland
Pervasive developmental disorder, unspecified
27.6
6.3
8
*
G41.9
ICD-10 Finland
Status epilepticus, unspecified
27.6
6.3
8
*
78020
ICD-8 Finland
Certain symptoms referable to nervous system and special senses, Convulsions
27.6
6.3
8
*
XA800
NOMESCO Finland
Neuropsychological investigation
4.0
6.2
24
66
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
9.0
6.1
12
14
R1250
NOMESCO Finland
Evaluation of functional capability
10.5
6.1
11
11
D01AC02
ATC
miconazole; topical
4.1
6.0
22
58
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3000081) cloZAPine [Moles/volume] in Serum or Plasma
15
19
8.38
11.14
14.3
24.1
nmol/l
1467.3
1269.2
0.34
15
19
(3023368) Bacteria identified in Blood by Culture
80
378
2.71
10.98
4.0
4.3
—
—
—
0
0
(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
130
779
2.54
10.84
10.7
9.1
mmol/l
1.2
1.2
0.08
114
678
(3008832) Norclozapine [Moles/volume] in Serum or Plasma
14
19
7.78
9.81
12.6
14.3
nmol/l
933.1
714.2
0.64
14
19
(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma
118
727
2.28
8.61
9.7
8.8
mmol/l
1.2
1.2
0.02
110
677
(43055554) Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
46
183
2.89
8.57
8.4
5.7
mmol/l
1.9
1.5
0.34
32
137
(3026008) Bacteria identified in Urine by Culture
81
434
2.34
8.14
5.0
2.7
—
—
—
0
0
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
54
250
2.52
7.42
1.9
1.8
—
—
—
0
0
(1761868) Lipid panel - Serum or Plasma
23
606
0.31
7.15
2.7
2.5
—
—
—
0
0
(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
41
175
2.63
6.62
1.8
1.6
—
—
—
0
0
(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
41
179
2.57
6.31
1.8
1.7
—
—
—
0
0
(3015235) Bicarbonate [Moles/volume] in Capillary blood
19
55
3.68
5.87
3.9
2.8
mmol/l
24.6
23.8
0.30
19
46
(3011397) Hemoglobin [Presence] in Urine by Test strip
69
394
2.07
5.63
4.3
3.0
—
—
—
0
0
(3002032) Base excess in Venous blood by calculation
46
224
2.32
5.57
5.4
8.3
mmol/l
0.7
1.8
1.66
37
166
(3019832) Treponema pallidum Ab [Presence] in Serum
6
266
0.20
5.51
3.2
1.8
—
—
—
0
0
(3019309) Folate [Moles/volume] in Red Blood Cells
42
202
2.32
5.22
1.7
1.5
nmol/l
1112.6
1257.6
0.58
36
160
(3042936) Bacteria identified in Isolate by Culture
45
223
2.27
5.22
1.8
2.2
—
—
—
0
0
(3003396) Base excess in Arterial blood by calculation
34
151
2.47
5.03
6.9
12.3
mmol/l
2.8
1.4
1.42
25
118
(3000991) Gas panel - Venous blood
42
206
2.27
4.98
8.1
10.0
—
—
—
0
0
(3032080) INR in Blood by Coagulation assay
84
535
1.90
4.93
10.0
6.8
inr
1.2
1.2
0.10
29
160
(3022313) Gas panel - Capillary blood
34
153
2.43
4.89
9.2
6.0
—
—
—
0
0
(40762366) Oxygen capacity [Volume Fraction] in Arterial blood
21
74
3.02
4.80
7.5
18.6
—
—
—
0
0
(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma
114
813
1.80
4.56
5.7
6.4
umol/l
8.3
12.6
4.45
108
766
(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
161
1277
1.87
4.49
7.1
6.6
u/l
88.9
86.4
0.21
154
1200
(3007853) Bacteria identified in Skin by Aerobe culture
41
211
2.15
4.31
2.3
1.6
—
—
—
0
0
(1616796) Gas panel - Central venous blood
13
36
3.77
4.27
5.5
4.5
—
—
—
0
0
(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
22
86
2.72
4.19
1.9
1.3
—
—
—
0
0
(44816844) Macroprolactin [Units/volume] in Serum or Plasma
12
32
3.90
4.14
1.4
1.3
—
—
—
0
0
(3009261) Glucose [Presence] in Urine by Test strip
115
839
1.74
4.13
5.0
3.4
estimate
0.0
0.0
0.00
19
137
(3035350) Ketones [Presence] in Urine by Test strip
114
831
1.74
4.10
4.8
3.3
estimate
0.0
0.0
0.00
19
145
(3014111) Lactate [Moles/volume] in Serum or Plasma
30
140
2.31
3.98
6.5
10.8
mmol/l
1.2
1.2
0.08
24
130
(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
47
263
1.99
3.95
1.6
1.7
pmol/l
520.0
462.0
0.62
41
224
(3029937) Albumin [Presence] in Urine by Test strip
67
422
1.83
3.95
5.0
3.7
estimate
0.0
0.0
0.50
20
141
(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
19
71
2.83
3.93
1.6
1.5
—
—
—
0
0
(3021601) Nitrite [Presence] in Urine by Test strip
113
830
1.71
3.89
6.5
4.6
estimate
0.0
0.0
0.00
20
145
(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
29
547
0.46
3.79
1.8
1.7
—
—
—
0
0
(3001604) Monocytes [#/volume] in Blood
129
987
1.70
3.78
8.6
7.2
e9/l
0.6
0.6
0.54
116
859
(3019198) Lymphocytes [#/volume] in Blood
132
1018
1.70
3.74
8.1
7.2
e9/l
2.1
2.0
0.20
121
909
(3006315) Basophils [#/volume] in Blood
129
990
1.69
3.71
8.6
7.2
e9/l
0.0
0.0
1.68
117
863
(40768804) Tissue Pathology biopsy report
34
600
0.49
3.65
2.1
1.9
—
—
—
0
0
(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma
78
526
1.73
3.61
3.1
3.3
ng/l
46.6
37.1
0.17
54
321
(3021960) Folate [Moles/volume] in Serum or Plasma
50
300
1.85
3.40
1.5
1.5
nmol/l
22.2
22.1
0.01
45
259
(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
96
694
1.66
3.39
2.9
2.7
nmol/l
78.3
71.6
1.24
88
639
(43054903) Holo-transcobalamin II [Moles/volume] in Serum
78
534
1.70
3.38
1.8
1.7
pmol/l
106.1
95.6
0.82
43
265
(3013115) Eosinophils [#/volume] in Blood
130
1018
1.64
3.32
9.3
7.9
e9/l
0.2
0.2
1.37
118
902
(36305247) Microscopic observation [Identifier] in Isolate by Gram stain
12
38
3.28
3.26
1.1
1.5
—
—
—
0
0
(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells
12
38
3.28
3.26
1.1
2.6
—
—
—
0
0
(3019150) Specific gravity of Urine by Refractometry
61
394
1.75
3.24
5.5
3.2
kg/l
1.0
1.0
0.55
15
47
(3033319) Streptococcus pyogenes Ag [Presence] in Throat
15
345
0.40
3.19
1.5
1.7
—
—
—
0
0
(3023520) Reticulocytes [#/volume] in Blood
28
140
2.14
3.17
2.9
4.6
e9/l
66.8
71.5
0.30
22
100
(42870588) Differential panel, method unspecified - Blood
94
689
1.62
3.07
8.0
7.7
—
—
—
0
0
(40758558) Short blood count panel - Blood
74
511
1.66
3.07
8.6
8.4
—
—
—
0
0
(3009542) Hematocrit [Volume Fraction] of Blood
158
1800
0.61
2.90
26.8
13.7
%
36.4
40.8
3.62
108
1482
(3019060) Gas panel - Arterial blood
20
90
2.34
2.89
4.7
9.5
—
—
—
0
0
(3018418) pH of Serum or Plasma
64
438
1.64
2.71
3.7
3.8
ph
7.4
7.4
0.70
15
79
(3000850) Epithelial cells [#/volume] in Urine
51
330
1.70
2.67
3.9
2.7
e6/l
9.7
4.9
0.56
39
291
(3024666) Lithium, Blood [Moles/volume] in Serum or Plasma
7
15
4.78
2.61
14.1
9.9
mmol/l
0.6
0.6
—
7
15
(3022621) pH of Urine by Test strip
20
95
2.21
2.57
6.3
2.1
—
—
—
0
0
(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
16
69
2.42
2.54
7.1
4.6
%
55.6
55.1
0.02
16
69
(3026782) Osmolality of Urine
50
326
1.68
2.54
4.4
3.0
mosm/kgh2o
514.4
570.7
0.79
41
280
(3000067) Parathyrin.intact [Mass/volume] in Serum or Plasma
25
132
2.00
2.47
6.2
5.5
ng/l
64.4
65.8
0.04
25
125
(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture
0
63
0.00
2.46
0.0
1.6
—
—
—
0
0
(3023601) Vancomycin resistant enterococcus [Presence] in Specimen by Organism specific culture
5
8
6.36
2.38
9.6
2.5
—
—
—
0
0
(3013650) Neutrophils [#/volume] in Blood by Automated count
135
1118
1.50
2.36
16.4
10.1
e9/l
4.2
3.9
0.54
123
972
(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood
18
85
2.21
2.36
4.4
7.0
%
1.3
1.4
0.20
18
85
(3014576) Chloride [Moles/volume] in Serum or Plasma
31
182
1.81
2.26
6.8
8.8
mmol/l
104.5
104.1
0.10
31
177
(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
18
339
0.49
2.25
3.6
2.3
—
—
—
0
0
(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection
10
36
2.86
2.23
1.8
1.6
—
—
—
0
0
(3000492) Spirometry study
7
178
0.37
2.14
1.6
1.4
—
—
—
0
0
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
21
369
0.53
2.12
3.4
2.4
—
—
—
0
0
(3019225) pH of Specimen
21
111
1.98
2.09
8.9
5.4
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
83
635
1.48
2.08
5.5
3.4
—
—
—
0
0
(3020682) Albumin/Creatinine [Ratio] in Urine
55
387
1.55
2.04
3.5
4.0
mg/mmol
7.9
12.6
0.53
38
257
(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
53
370
1.56
2.03
2.7
3.6
ng/l
856.6
1068.5
0.29
46
306
(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
19
337
0.52
1.98
3.8
3.5
%
22.7
20.5
—
5
126
(3020630) Protein [Mass/volume] in Serum or Plasma
18
92
2.04
1.96
2.6
3.9
g/l
70.4
65.5
1.99
18
84
(46235355) HIV 1 and 2 tests - Meaningful Use set
31
477
0.60
1.95
2.7
2.0
—
—
—
0
0
(3005033) Fetal Nuchal fold Thickness US
0
50
0.00
1.91
0.0
1.5
—
—
—
0
0
(3047352) Trisomy 18 risk [Likelihood] in Fetus
0
50
0.00
1.91
0.0
1.5
—
—
—
0
0
(3043238) Trisomy 21 risk [Likelihood] in Fetus
0
52
0.00
1.90
0.0
1.6
—
—
—
0
0
(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma
0
52
0.00
1.90
0.0
1.5
—
—
—
0
0
(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
20
108
1.93
1.88
2.1
2.1
—
—
—
0
0
(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma
42
283
1.59
1.87
3.4
3.5
ng/l
385.4
401.2
0.02
32
204
(3020717) Zinc [Moles/volume] in Serum or Plasma
6
18
3.39
1.76
2.3
1.2
umol/l
13.6
12.6
—
6
18
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
75
582
1.43
1.70
4.5
3.6
—
—
—
0
0
(3019284) Hepatitis B virus surface Ag [Presence] in Serum
24
381
0.59
1.70
2.2
1.6
—
—
—
0
0
(3018010) Neutrophils/100 leukocytes in Blood
115
963
1.39
1.68
9.0
7.0
%
53.8
55.2
0.45
110
920
(3017181) Myelocytes/100 leukocytes in Blood
22
128
1.79
1.67
3.4
4.5
%
0.8
0.9
0.13
12
39
(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
54
397
1.47
1.62
2.1
2.9
mg/l
2.6
2.8
0.30
49
341
(3000494) Fungus identified in Specimen by Culture
30
193
1.64
1.61
1.4
1.7
—
—
—
0
0
(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting
138
1554
0.72
1.61
3.6
3.4
mmol/l
1.4
1.3
1.01
129
1443
(3004119) Hemoglobin [Mass/volume] in Venous blood
17
92
1.92
1.61
4.7
7.6
g/l
128.2
131.9
0.41
17
92
(3012516) Albumin [Mass/volume] in Urine
50
363
1.48
1.60
3.1
3.2
mg/l
1307.2
268.1
0.37
37
249
(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma
154
1363
1.39
1.56
4.7
3.7
pmol/l
14.3
14.7
0.70
143
1257
(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma
148
1644
0.72
1.55
4.6
4.1
mmol/l
2.5
2.8
3.59
141
1528
(40761535) Cells panel - Urine sediment
19
109
1.81
1.52
3.9
3.7
—
—
—
0
0
(3012336) Haptoglobin [Mass/volume] in Serum or Plasma
13
65
2.06
1.52
1.4
1.9
g/l
1.4
1.3
0.25
13
57
(3032035) Polymorphonuclear cells/100 leukocytes in Blood
9
37
2.49
1.49
6.2
4.1
%
53.9
56.3
—
9
37
(3030905) Polymorphonuclear cells [#/volume] in Blood
9
37
2.49
1.49
4.7
4.0
e9/l
3.8
4.3
—
9
37
(3027315) Oxygen [Partial pressure] in Blood
9
37
2.49
1.49
7.8
3.9
kpa
8.7
8.8
—
9
37
(3013290) Carbon dioxide [Partial pressure] in Blood
9
37
2.49
1.49
7.8
3.9
kpa
5.6
5.0
—
9
37
(3019900) Cholesterol [Moles/volume] in Serum or Plasma
146
1621
0.73
1.48
3.9
3.8
mmol/l
4.3
4.6
4.57
140
1521
(3022145) Colonoscopy Study observation
9
177
0.49
1.47
1.2
1.4
—
—
—
0
0
(3002582) Erythrocytes [#/volume] in Urine
65
504
1.40
1.46
5.0
3.3
e6/l
37.8
24.1
0.27
51
389
(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma
145
1608
0.73
1.42
4.0
3.7
mmol/l
1.3
1.4
3.81
138
1494
(3005322) IgE [Units/volume] in Serum or Plasma
7
146
0.46
1.37
1.0
1.4
u/ml
169.4
402.2
—
7
131
(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
6
23
2.65
1.37
1.3
1.4
—
—
—
0
0
(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
26
169
1.61
1.36
3.3
4.7
u/l
209.3
260.4
1.80
26
162
(3039443) Prostate specific Ag panel - Serum or Plasma
0
37
0.00
1.35
0.0
1.5
—
—
—
0
0
(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
21
129
1.69
1.35
5.6
3.4
—
—
—
0
0
(3005136) Cladosporium herbarum IgE Ab [Units/volume] in Serum
0
40
0.00
1.34
0.0
1.1
—
0.4
—
0
14
(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
11
55
2.05
1.29
2.2
2.1
—
—
—
0
0
(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma
24
155
1.61
1.29
5.9
6.4
—
—
—
0
0
(3025468) Yersinia sp identified in Specimen by Organism specific culture
5
18
2.82
1.29
1.4
1.9
—
—
—
0
0
(4198724)
5
18
2.82
1.29
2.4
1.3
—
—
—
0
0
(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
15
250
0.57
1.28
1.7
2.5
ug/l
0.9
0.6
—
7
138
(3021901) Oxygen saturation in Capillary blood
8
35
2.33
1.28
2.0
2.7
—
—
—
0
0
(3027273) Bicarbonate [Moles/volume] in Venous blood
13
70
1.91
1.26
5.8
4.4
mmol/l
24.1
24.0
0.08
13
70
(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection
5
19
2.67
1.22
1.4
1.8
—
—
—
0
0
(3005988) Vibrio sp identified in Specimen by Organism specific culture
5
19
2.67
1.22
1.4
1.8
—
—
—
0
0
(3021589) Normoblasts [#/volume] in Blood
104
894
1.30
1.15
9.5
10.5
e9/l
0.0
0.0
0.34
87
712
(3024928) Oxygen saturation in Venous blood
8
40
2.04
1.13
1.6
11.2
—
—
—
0
0
(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma
30
212
1.48
1.11
4.0
4.3
umol/l
4.3
8.1
1.88
23
191
(3006184) Hemoglobin [Mass/volume] in Capillary blood
8
41
1.98
1.10
1.4
2.5
g/l
128.9
132.8
—
8
28
(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma
7
32
2.22
1.09
8.3
4.7
—
—
—
0
0
(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
10
52
1.97
1.08
2.3
1.9
—
—
—
0
0
(40761536) Microorganisms panel - Urine sediment
21
139
1.56
1.04
6.1
3.9
—
—
—
0
0
(3037467) Urinalysis macro (dipstick) panel - Urine
129
1150
1.28
1.04
6.3
4.1
—
—
—
0
0
(3035637) Corticotropin [Mass/volume] in Plasma
9
47
1.95
1.03
1.6
1.7
—
—
—
0
0
(3044640) Blood type and Crossmatch panel - Blood
64
522
1.31
1.03
2.7
2.5
—
—
—
0
0
(3050238) Crystals [Presence] in Synovial fluid by Light microscopy
7
35
2.03
1.01
2.0
1.3
—
—
—
0
0
(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
12
197
0.59
0.99
2.3
2.2
—
—
—
0
0
(4034850)
10
54
1.89
0.98
6.0
11.8
—
—
—
0
0
(3021440) Promyelocytes/100 leukocytes in Blood
18
117
1.58
0.97
3.7
4.6
%
0.0
0.2
—
9
35
(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)
165
1525
1.29
0.96
14.2
10.1
ml/min/173m2
101.7
90.2
4.09
123
1179
(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
16
241
0.64
0.94
1.3
1.4
—
—
—
0
0
(43054914) Glucose tolerance 2 hours panel - Serum or Plasma
9
155
0.56
0.92
1.6
1.9
—
—
—
0
0
(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum
18
262
0.66
0.90
1.2
1.3
u/ml
17.2
7.2
—
7
95
(3013512) EKG study
47
375
1.32
0.88
5.2
3.5
—
—
—
0
0
(3009201) Thyrotropin [Units/volume] in Serum or Plasma
172
1605
1.28
0.88
5.7
4.3
mu/l
1.9
1.9
0.22
161
1487
(44816559) Phosphatidylethanol [Mass/volume] in Blood
8
45
1.81
0.85
1.4
1.2
—
—
—
0
0
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
48
387
1.30
0.84
2.6
2.6
—
—
—
0
0
(3045414) Leukocytes [Presence] in Urine
11
65
1.73
0.84
2.2
1.5
—
—
—
0
0
(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
6
33
1.84
0.79
1.3
1.4
—
—
—
0
0
(3048689) Calprotectin [Mass/mass] in Stool
25
333
0.72
0.79
1.4
2.8
ug/g
111.6
105.7
0.07
19
269
(3018095) Leukocytes [#/volume] in Urine
70
597
1.25
0.78
6.1
3.8
e6/l
532.3
38.3
0.53
50
413
(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection
6
34
1.78
0.77
1.0
1.6
—
—
—
0
0
(3025159) Blasts/100 leukocytes in Blood
17
116
1.50
0.76
3.8
4.6
%
0.0
0.3
—
6
33
(3004716) Salmonella sp identified in Stool by Organism specific culture
8
134
0.58
0.76
1.0
1.2
—
—
—
0
0
(3030467) Casts [#/volume] in Urine by Automated count
56
468
1.26
0.75
4.9
3.3
e6/l
0.4
0.3
0.23
45
351
(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
9
55
1.66
0.74
1.1
1.7
—
—
—
0
0
(3016251) Hemoglobin.gastrointestinal [Presence] in Stool
13
84
1.58
0.73
2.1
2.2
—
—
—
0
0
(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
9
56
1.63
0.73
1.2
1.6
—
—
—
0
0
(3044290) Cell count panel - Cerebral spinal fluid
7
39
1.82
0.73
2.3
3.3
—
—
—
0
0
(3052851) Hemolysis interference index of Serum or Plasma
9
57
1.60
0.72
3.6
2.6
—
—
—
0
0
(3045424) Erythrocytes [Presence] in Urine
5
26
1.94
0.71
1.4
1.2
—
—
—
0
0
(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay
7
42
1.69
0.69
1.0
1.2
—
—
—
0
0
(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay
7
42
1.69
0.69
1.0
1.2
—
—
—
0
0
(3042596) Human coronavirus RNA [Presence] in Specimen by NAA with probe detection
5
28
1.80
0.66
1.2
1.8
—
—
—
0
0
(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing
5
28
1.80
0.66
1.8
1.5
—
—
—
0
0
(4010399)
8
131
0.60
0.65
1.4
1.4
—
—
—
0
0
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
84
745
1.20
0.64
4.3
4.2
—
—
—
0
0
(3025941) Bacteria identified in Stool by Culture
15
105
1.46
0.61
1.3
1.3
—
—
—
0
0
(3025547) Thyroglobulin Ab [Units/volume] in Serum or Plasma
0
23
0.00
0.58
0.0
3.3
—
157.8
—
0
5
(3020891) Body temperature
9
61
1.49
0.54
4.6
5.3
—
—
—
0
0
(3020460) C reactive protein [Mass/volume] in Serum or Plasma
190
1827
1.23
0.54
20.1
12.0
mg/l
25.2
22.2
0.71
160
1368
(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count
33
270
1.26
0.54
3.8
3.1
e6/l
3.0
1.8
0.28
20
153
(4035726)
9
133
0.66
0.53
1.6
1.5
—
—
—
0
0
(3017143) Hepatitis C virus Ab [Presence] in Serum
22
278
0.77
0.51
2.2
1.6
—
—
—
0
0
(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
9
65
1.40
0.51
1.9
1.9
—
—
—
0
0
(3013139) Helicobacter pylori Ag [Presence] in Stool
14
101
1.41
0.51
1.2
1.1
—
—
—
0
0
(46236952) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)
15
110
1.39
0.50
2.9
2.5
ml/min/173m2
76.8
76.1
—
5
42
(3021879) Hepatitis B virus core Ab [Presence] in Serum
13
177
0.72
0.49
1.3
1.5
—
—
—
0
0
(3027475) Erythrocytes [#/volume] in Cerebral spinal fluid
7
46
1.54
0.48
2.4
3.0
e6/l
455.3
291.5
—
7
37
(3016543) Leukocytes [#/volume] in Cerebral spinal fluid
7
46
1.54
0.48
2.3
2.9
e6/l
4.4
3.3
—
7
37
(3002256) Pathology report gross observation
13
176
0.72
0.48
1.1
1.2
—
—
—
0
0
(3028300) Cannabinoids [Presence] in Urine
12
164
0.72
0.47
2.6
1.5
—
—
—
0
0
(3027008) Opiates [Presence] in Urine
12
163
0.72
0.45
2.6
1.5
—
—
—
0
0
(3027944) Amphetamines [Presence] in Urine
12
163
0.72
0.45
2.6
1.5
—
—
—
0
0
(3000764) Benzodiazepines [Presence] in Urine
12
162
0.73
0.44
2.6
1.5
—
—
—
0
0
(3003694) ABO and Rh group [Type] in Blood
49
557
0.85
0.44
1.3
1.5
—
—
—
0
0
(3044889) 12 lead EKG panel
114
1063
1.14
0.43
3.7
3.3
—
—
—
0
0
(3013327) Hepatitis A virus IgM Ab [Presence] in Serum
5
31
1.63
0.43
1.0
1.0
—
—
—
0
0
(44790047)
5
31
1.63
0.43
1.2
1.7
—
—
—
0
0
(44806118)
5
31
1.63
0.43
1.2
1.7
—
—
—
0
0
(44790048)
5
31
1.63
0.43
1.2
1.7
—
—
—
0
0
(44790049)
5
31
1.63
0.43
1.2
1.7
—
—
—
0
0
(3014051) Protein [Presence] in Urine by Test strip
5
32
1.57
0.42
3.0
1.6
—
—
—
0
0
(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
12
160
0.74
0.41
2.1
2.0
—
—
—
0
0
(3012447) Hantavirus puumala IgG Ab [Titer] in Serum
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
(3049539) Genetic diseases [Identifier] in Blood or Tissue by FISH Nominal
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
(3015183) Erythrocyte sedimentation rate
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
(3013180) HIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification
0
16
0.00
0.41
0.0
6.5
—
39.4
—
0
5
(40768795) Lymph node Pathology biopsy report
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
(3027544) Mycobacterium sp identified in Sputum by Organism specific culture
0
17
0.00
0.41
0.0
3.8
—
—
—
0
0
(3020393) Adenovirus Ag [Presence] in Stool
0
17
0.00
0.41
0.0
2.3
—
—
—
0
0
(3015635) Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
8
60
1.35
0.40
2.3
1.8
—
—
—
0
0
(3016888) Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7
103
0.67
0.40
1.1
1.2
—
17.9
—
0
5
(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
8
61
1.32
0.40
2.3
1.8
—
—
—
0
0
(36304419) Bacteria [Presence] in Urine
52
461
1.17
0.39
5.1
3.2
—
—
—
0
0
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
145
1518
0.88
0.39
3.6
3.6
—
—
—
0
0
(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight
0
19
0.00
0.39
0.0
1.5
—
—
—
0
0
(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection
5
36
1.40
0.38
1.0
1.6
—
—
—
0
0
(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay
9
68
1.34
0.38
1.4
1.8
—
—
—
0
0
(3000330) Specific gravity of Urine by Test strip
10
72
1.41
0.37
2.7
3.4
—
—
—
0
0
(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum
62
560
1.15
0.37
1.4
1.5
u/ml
0.4
1.6
3.83
16
135
(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
41
359
1.17
0.36
2.3
2.9
mg/l
1.3
1.2
0.07
34
271
(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum
5
79
0.62
0.36
1.4
1.2
—
—
—
0
0
(40761511) CBC panel - Blood by Automated count
197
1921
1.18
0.34
19.6
10.4
—
—
—
0
0
(3016879) Cocaine [Presence] in Urine
12
154
0.77
0.33
2.6
1.5
—
—
—
0
0
(3028707) Methadone [Presence] in Urine by Screen method
10
74
1.37
0.33
2.8
1.6
—
—
—
0
0
(1001926) Buprenorphine [Presence] in Urine by Screen method
10
131
0.75
0.31
2.5
1.5
—
—
—
0
0
(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection
7
52
1.36
0.31
1.3
1.4
—
—
—
0
0
(3008898) HLA-B27 [Presence]
7
99
0.70
0.31
1.0
1.0
—
—
—
0
0
(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
9
76
1.19
0.25
4.7
6.4
%
176.7
175.6
—
9
76
(3041096) Erythrocytes [Presence] in Urine by Automated
51
468
1.12
0.24
4.9
3.2
—
—
—
0
0
(3048929) Epstein Barr virus Ab [Presence] in Serum
10
125
0.79
0.23
1.4
1.6
—
—
—
0
0
(1761482) Bacteria [#/volume] in Urine by Culture
5
40
1.26
0.22
2.2
4.6
—
—
—
0
0
(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain
5
41
1.22
0.22
1.6
1.2
—
—
—
0
0
(3011831) Apolipoprotein B/Apolipoprotein A-I [Percentile]
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
(3008364) Apolipoprotein A-I [Mass/volume] in Serum or Plasma
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
(3008092) Baker's yeast IgG Ab [Units/volume] in Serum
0
11
0.00
0.21
0.0
1.4
—
21.4
—
0
5
(1617658) Protocol used for examination of sentinel lymph nodes
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay
0
11
0.00
0.21
0.0
2.3
—
108.9
—
0
11
(3041672) Baker's yeast Ab [Presence] in Serum
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
(3009550) Parvovirus B19 IgG Ab [Titer] in Serum
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
(40761995) Spermatozoa Progressive [#/volume] in Semen
0
12
0.00
0.21
0.0
2.5
—
—
—
0
0
(3026048) Bordetella pertussis IgG Ab [Units/volume] in Serum
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
(3014043) Spermatozoa Nonprogressive/100 spermatozoa in Semen
0
12
0.00
0.21
0.0
5.0
—
—
—
0
0
(3027231) Wheat IgE Ab [Units/volume] in Serum
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
(3027953) Aldolase [Enzymatic activity/volume] in Serum or Plasma
0
12
0.00
0.21
0.0
1.4
—
8.4
—
0
12
(3026515) Parvovirus B19 IgM Ab [Units/volume] in Serum
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
(1001509) Gas and Carbon monoxide and Electrolytes panel - Arterial blood
0
12
0.00
0.21
0.0
2.2
—
—
—
0
0
(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
5
43
1.17
0.21
1.0
1.6
—
—
—
0
0
(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
5
43
1.17
0.21
1.6
2.9
—
—
—
0
0
(40760847) Basement membrane Ab [Titer] in Serum by Immunofluorescence
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
(3042299) inFLIXimab [Mass/volume] in Serum or Plasma
0
13
0.00
0.21
0.0
11.9
—
8.1
—
0
13
(3035320) C reactive protein [Mass/volume] in Body fluid
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
(40762119) U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
(3014791) Apolipoprotein B [Mass/volume] in Serum or Plasma
0
14
0.00
0.20
0.0
1.5
—
1.0
—
0
14
(3053028) Streptococcus sp identified in Specimen by Organism specific culture
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
(42868674) Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
17
146
1.18
0.20
4.0
4.0
%
34.8
31.3
0.74
12
101
(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
5
70
0.71
0.17
1.0
1.4
—
—
—
0
0
(40768797) Stomach Pathology biopsy report
17
193
0.87
0.16
1.3
1.3
—
—
—
0
0
(3004588) Protein electrophoresis panel - Serum or Plasma
8
71
1.13
0.16
1.3
3.1
—
—
—
0
0
(3001122) Ferritin [Mass/volume] in Serum or Plasma
77
802
0.94
0.14
3.2
2.9
ug/l
100.7
88.6
0.39
69
749
(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
8
98
0.81
0.14
2.0
2.1
—
—
—
0
0
(3007164) IgA [Mass/volume] in Serum or Plasma
48
504
0.94
0.11
1.6
1.6
g/l
2.1
2.0
0.02
25
294
(3020961) Endomysium IgA Ab [Titer] in Serum
13
146
0.88
0.10
1.2
1.2
—
10.0
—
0
5
(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count
30
281
1.08
0.10
3.2
3.0
e6/l
0.5
0.7
0.40
16
163
(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum
6
54
1.11
0.09
1.3
1.2
—
—
—
0
0
(40766189) Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay
6
57
1.05
0.08
1.0
1.0
—
14.8
—
0
7
(40768443) Skin Pathology biopsy report
5
62
0.80
0.08
1.0
1.1
—
—
—
0
0
(43534045) MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
17
156
1.10
0.08
1.0
1.0
—
—
—
0
0
(3017895) Helicobacter pylori Ab [Units/volume] in Serum
8
75
1.07
0.07
1.3
1.7
—
—
—
0
0
(3003191) Choriogonadotropin (pregnancy test) [Presence] in Serum or Plasma
7
80
0.87
0.07
1.0
1.7
—
—
—
0
0
(3027238) Thyroperoxidase Ab [Units/volume] in Serum or Plasma
11
122
0.90
0.07
1.1
1.2
iu/ml
19.9
131.9
—
5
43
(36660697) Celiac disease serology panel - Serum
23
217
1.07
0.06
1.3
1.2
—
—
—
0
0
(40760892) CBC W Ordered Manual Differential panel - Blood
44
425
1.04
0.06
8.4
4.7
—
—
—
0
0
(3018251) Fasting glucose [Moles/volume] in Serum or Plasma
160
1586
1.03
0.04
4.5
3.7
mmol/l
6.1
5.8
0.95
153
1465
(3011288) Drugs identified in Urine by Screen method
12
112
1.08
0.03
3.8
1.8
—
—
—
0
0
(3004410) Hemoglobin A1c/Hemoglobin.total in Blood
145
1446
1.01
0.00
6.0
4.9
mmol/mol
40.8
38.9
0.91
137
1363
(3013707) Erythrocyte sedimentation rate by Westergren method
128
1278
1.00
0.00
4.6
4.3
mm/h
12.3
9.2
1.52
123
1192
(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
123
1227
1.01
0.00
3.9
3.3
u/l
45.9
39.6
0.63
116
1168
(3006418) Campylobacter sp identified in Tissue by Organism specific culture
6
67
0.89
0.00
1.0
1.1
—
—
—
0
0
(3018921) Toxoplasma gondii IgA Ab [Units/volume] in Serum
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(36306090) Helicobacter pylori [Presence] in Tissue by Organism specific culture
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3021578) Parainfluenza virus 2 Ag [Presence] in Specimen
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3029075) Extractable nuclear Ab panel - Serum
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
(3012320) Pathologist interpretation of Cerebral spinal fluid tests
0
7
0.00
0.00
0.0
2.6
—
—
—
0
0
(3025378) Microscopic observation [Identifier] in Cervix by Cyto stain
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3016724) Homocysteine [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.4
—
10.6
—
0
5
(3032352) Blasts [#/volume] in Cerebral spinal fluid
0
6
0.00
0.00
0.0
6.0
—
—
—
0
0
(3023511) Choriogonadotropin [Units/volume] in Urine
7
76
0.92
0.00
2.3
1.2
—
—
—
0
0
(3005011) Chlamydia sp Ab [Titer] in Serum
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
(3016845) Adenovirus Ag [Presence] in Specimen by Immunofluorescence
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
(3005593) Pancreatic islet cell Ab [Titer] in Serum
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3035401) Herpes virus 6 DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3036432) Mycobacterium tuberculosis genotype [Identifier] in Isolate
0
6
0.00
0.00
0.0
19.5
—
—
—
0
0
(42870298) TPMT gene c.238G>C+460G>A+719A>G [Identifier] in Blood or Tissue by Molecular genetics method Narrative
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(42868414) European tick borne encephalitis virus IgM Ab [Presence] in Serum by Immunoassay
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(40757349) CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Blood
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
(42529406) Shigella sp [Presence] in Stool by Culture
6
68
0.88
0.00
1.0
1.1
—
—
—
0
0
(40760109) Toxoplasma gondii IgG Ab avidity [Ratio] in Serum by Immunoassay
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3020650) Glucose [Presence] in Urine
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3024891) Influenza virus A+B Ag [Presence] in Specimen
7
76
0.92
0.00
1.0
1.1
—
—
—
0
0
(44806420)
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
(3019497) Choriogonadotropin.beta subunit free [Moles/volume] in Serum or Plasma
0
9
0.00
0.00
0.0
2.1
—
—
—
0
0
(3051252) Vasoactive intestinal peptide [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
2.4
—
15.1
—
0
5
(40760848) Basement membrane zone BP180 Ab [Units/volume] in Serum by Immunoassay
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
(3007798) IgG/Albumin [Mass Ratio] in Cerebral spinal fluid
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(21493195) Respiratory pathogens DNA and RNA tested for in Respiratory system specimen by NAA with probe detection
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
(3022058) Hepatitis B virus DNA [Presence] in Serum or Plasma by NAA with probe detection
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
(4133840)
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(40768806) Pleura Pathology biopsy report
0
6
0.00
0.00
0.0
2.3
—
—
—
0
0
(46235128) Lupus anticoagulant aPTT and dRVVT screening panel W Reflex
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3014765) Yersinia sp identified in Stool by Organism specific culture
6
68
0.88
0.00
1.0
1.1
—
—
—
0
0
(3002621) Streptococcal DNAse B [Units/volume] in Serum
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
(44806071)
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3021513) Carbon dioxide [Partial pressure] in Mixed venous blood
0
6
0.00
0.00
0.0
7.0
—
—
—
0
0
(3013247) Albumin in CSF/Albumin in Serum or Plasma
0
5
0.00
0.00
0.0
1.0
—
4.2
—
0
5
(3028679) Herpes simplex virus Ab [Presence] in Serum
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
(42869547) Procollagen type III.N-terminal propeptide [Mass/volume] in Serum
0
6
0.00
0.00
0.0
1.3
—
7.5
—
0
6
(3005156) Respiratory syncytial virus A RNA [Presence] in Specimen by NAA with probe detection
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
(3037692) Legionella sp identified in Specimen by Organism specific culture
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3007821) Glucose [Moles/volume] in Serum or Plasma --baseline
0
6
0.00
0.00
0.0
1.2
—
9.6
—
0
6
(3037556) Urate [Mass/volume] in Serum or Plasma
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3045209) Lutropin/Follitropin [Ratio] in Serum or Plasma
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3022689) Creatine [Moles/volume] in Urine
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3029715) Chromosome analysis.interphase [Interpretation] in Bone marrow by FISH Narrative
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3022575) Varicella zoster virus IgG Ab [Units/volume] in Serum
0
7
0.00
0.00
0.0
1.0
—
1722.3
—
0
7
(3038071) Oxygen [Partial pressure] in Mixed venous blood
0
6
0.00
0.00
0.0
7.0
—
—
—
0
0
(3000108) Respiratory syncytial virus B RNA [Presence] in Specimen by NAA with probe detection
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
(3005880) Parainfluenza virus 3 Ag [Presence] in Specimen
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(40771527) Human papilloma virus E6+E7 mRNA [Presence] in Cervix by NAA with probe detection
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(3021197) Magnesium Ionized [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
4.0
—
—
—
0
0
(3034426) Prothrombin time (PT)
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
(44786774) Adalimumab [Mass/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
4.0
—
14.1
—
0
5
(3010464) Parainfluenza virus 1 Ag [Presence] in Specimen
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3016273) Islet cell 512 Ab [Units/volume] in Serum
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
(3028334) Neisseria gonorrhoeae [Presence] in Specimen by Organism specific culture
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
(3004451) EKG impression Narrative
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
(42868766) Dientamoeba fragilis DNA [Presence] in Stool by NAA with probe detection
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
(3036535) Thyroglobulin [Mass/volume] in Serum or Plasma
0
8
0.00
-0.00
0.0
6.8
—
—
—
0
0
(3041806) Other cells [#/volume] in Blood by Manual count
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
(37020300) Entamoeba histolytica DNA [Presence] in Stool by NAA with probe detection
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint F5_MODRET and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| F5_MODRET | 6.615 [5.16, 8.48] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.1 |
During the follow-up period (1.1.1998 — 31.12.2019), 265 out of 1858 females with F5_MODRET died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| F5_MODRET | 3.444 [2.87, 4.13] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 284 out of 2621 males with F5_MODRET died.
Mortality risk
Mortality risk for people of age
years, who have F5_MODRET.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.543% | 0.549% |
| 5 | 3.359% | 3.302% |
| 10 | 8.41% | 8.733% |
| 15 | 16.665% | 16.144% |
| 20 | 26.975% | 26.716% |
Relationships between endpoints
↥Index endpoint: F5_MODRET – Moderate mental retardation
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data